A Digital Future: Evolving Beyond Decentralized Trials

The acceleration of digital transformation, in the wake of COVID-19, has had a significant impact on the industry. New technologies and tools enable decentralized clinical trials that help speed execution for specific processes. Yet, the addition of multiple function-specific eClinical applications to an already complex systems landscape makes it more difficult to run trials efficiently.

Nearly all sponsors and CROs report significant challenges with decentralized trials, including site technology adoption and increased burden for technology-averse patients. Only 56% say that the shift to decentralization has improved the patient experience, and less than a third say they have seen improvements in site engagement.

Pharmaceutical companies, biotechs, and CROs are rethinking their trial strategies and moving beyond decentralization for a more connected and digital trial model. The outlook is bright for clinical trials, and several companies–like AbbVie, Bayer, Celerion, GSK, Labcorp, and LEO Pharma–are helping to pave the path to the future.

The following eBook provides insights into the key challenges of decentralized trials, how the industry can advance toward a digital and connected future, and the critical need for a strong data foundation. It also showcases a top 20 pharma, Bayer, and how they are taking steps to enable digital execution for seamless data exchange in trials.